Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

By H. Colhoun, D. J. Betteridge, P. Durrington, G. Hitman, H. W. Neil, S. Livingstone, M. Thomason, M. Mackness, V. Charlton-menys, J. Fuller. The Lancet, 2004

3,713 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/76483f997fe0c7d9eea72efc792ccc924b3332de

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. V. Basevi
2. S. Grundy
3. I. Graham
4. R. Eckel
5. D. Lloyd‐Jones
6. J. Forbes
7. L. Rydén
8. M. Cooper

In Surgery

1. D. Lloyd‐Jones
2. J. Forbes
3. I. Graham
4. M. Cooper
5. Silvio E. Inzucchi
6. C. Bushnell
7. I. Hirsch
8. K. ‐. Tseng

Citations in the corpus

• National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, methodology): “8).(4,20,80,91,92,98,116) For these reasons, they are considered to be first-line drug treatment in both primary and secondary prevention of ASCVD.”
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “Specific statins and doses are noted in bold that were evaluated in RCTs (17,18,46-48,64-67,69-78) included in CQ1, CQ2 and the CTT 2010 meta-analysis included in CQ3 (20).”